Blood Flow Restriction Following Hip Arthroscopy (NCT04113759) | Clinical Trial Compass
RecruitingNot Applicable
Blood Flow Restriction Following Hip Arthroscopy
United States56 participantsStarted 2023-08-01
Plain-language summary
This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.
Who can participate
Age range18 Years – 40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients 18-40
* English-speaking
* Clinical and radiographic examination (MRI) consistent FAIS and/or labral pathology, and are schedule for primary hip arthroscopy
* Written and informed consent for study participation
Exclusion Criteria:
* Patients younger than 18 or older than 40 years of age
* Non-native English speaker
* Revision surgery or prior history of ipsilateral hip or knee surgery
* Inability to comply with the proposed follow-up clinic visits
* Patients lacking decisional capacity
* Patients with a history of deep vein thrombosis, pulmonary embolism, or known clotting disorder or hypercoagulable state
* Pregnant or breast-feeding women. Pregnancy as determined by a positive pregnancy test prior to procedure. Females of childbearing potential must agree to use an acceptable birth control method during study participation.
* Worker's compensation patients
* Any clinically significant finding that would place the patient at health risk, impact the study, or affect the completion of the study
* Any psychiatric illness that would prevent comprehension of the details and nature of the study and interfere with follow-up clinic visits